Latest Biotech News

Natera presented real‑world data at ASH showing that circulating tumor DNA (ctDNA) minimal residual disease testing at end‑of‑treatment was prognostic across lymphoma subtypes and outperformed PET...

Researchers implanted a genetically engineered pig liver into a human patient and demonstrated the graft could support key liver functions for an extended period before complications required its...

Gilead Sciences and partner Arcellx reported pivotal-stage data showing deep and durable responses for anito-cel in multiple myeloma, with a 96% overall response rate and 74% complete remission...

Vertex reported early results showing its CRISPR-based therapy Casgevy produced clinical benefit in pediatric patients with sickle cell disease and transfusion-dependent beta-thalassemia,...

At ASH, Natera presented real-world data showing circulating tumor DNA (ctDNA) — a minimal residual disease (MRD) assay — was prognostic across lymphoma subtypes and outperformed PET scans at end...

Cosmo Pharmaceuticals released topline results from two Phase III SCALP trials for clascoterone 5% topical solution in androgenetic alopecia, reporting a combined 252% relative improvement in...

Fulcrum Therapeutics reported that a higher dose of pociredir raised levels of fetal hemoglobin from 7.1% to 16.9% in 12 participants, presented at ASH. The company argued the data support...

Incyte presented preliminary results from a study of an investigational agent that targets calreticulin-mutant myelofibrosis, showing meaningful spleen responses and symptom improvements in...

Protagonist Therapeutics and Takeda presented longer-term Phase 3 data showing rusfertide reduced the need for therapeutic phlebotomy in patients with polycythemia vera. Results were disclosed at...

Star Therapeutics reported preliminary phase 1/2 data showing its once-monthly injection substantially reduced bleeding rates in patients with von Willebrand disease and has started dosing in a...

IDEA Pharma and SAI MedPartners released the inaugural China Pharmaceutical Innovation and Invention Index, ranking Hengrui and BeOne at the top for invention and innovation. The report evaluated...

Researchers implanted a genetically modified pig liver into a human and demonstrated that the xenograft could perform core hepatic functions for an extended period before surgical removal was...

Gilead Sciences and partner Arcellx reported pivotal-stage results for anito-cel in multiple myeloma showing deep, durable responses with acceptable safety. In the analysis of 117 patients...

Vertex reported that its CRISPR-based therapy Casgevy reached early efficacy goals in children with sickle cell disease and beta-thalassemia, supporting efforts to expand the label and accelerate...

Presentations at ASH preview data suggesting exa-cel (Casgevy) could provide a one-time functional cure for children aged 5–11 with transfusion-dependent beta-thalassemia or sickle cell disease....

Fulcrum Therapeutics presented early ASH data showing a higher dose of its oral candidate pociredir increased levels of fetal hemoglobin in patients with sickle cell disease. In the small cohort...

Incyte disclosed preliminary results for an experimental myelofibrosis agent that produced meaningful spleen-volume reductions and symptom improvements in advanced patients, according to ASH...

Researchers presented the largest prospective pooled dataset to date linking multiparameter flow cytometry minimal residual disease (MRD) status with overall survival in acute myeloid leukemia,...

AstraZeneca reported preliminary Western-patient data for its dual-target CAR‑T showing response rates consistent with earlier China-only studies, according to ASH disclosures. Early investigators...

A BioCentury report detailed that semaglutide, a GLP‑1 analogue laterally explored for neuroinflammation, did not demonstrate the expected anti-inflammatory effects in the central nervous system...